bioAffinity Technologies (NASDAQ:BIAF) Shares Up 2.7% – Still a Buy?

bioAffinity Technologies, Inc. (NASDAQ:BIAF) shares shot up 2.7% on Tuesday . The stock traded as high as $0.52 and last traded at $0.51. 272,658 shares were traded during trading, a decline of 89% from the average session volume of 2,470,132 shares. The stock had previously closed at $0.50.

Analyst Ratings Changes

Separately, Maxim Group reissued a “hold” rating on shares of bioAffinity Technologies in a report on Tuesday, April 1st.

bioAffinity Technologies Trading Up 2.7 %

The firm has a market cap of $9.31 million, a PE ratio of -0.62 and a beta of 3.45. The company has a 50-day simple moving average of $0.52 and a 200 day simple moving average of $0.91. The company has a current ratio of 1.02, a quick ratio of 1.01 and a debt-to-equity ratio of 0.18.

bioAffinity Technologies (NASDAQ:BIAF) last announced its quarterly earnings results on Monday, March 31st. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). bioAffinity Technologies had a negative return on equity of 205.09% and a negative net margin of 91.22%. The firm had revenue of $2.20 million for the quarter, compared to analysts’ expectations of $2.42 million.

Hedge Funds Weigh In On bioAffinity Technologies

A hedge fund recently raised its stake in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC grew its holdings in bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 46,304 shares of the company’s stock after buying an additional 26,304 shares during the quarter. Sheaff Brock Investment Advisors LLC owned 0.30% of bioAffinity Technologies worth $42,000 as of its most recent SEC filing. Institutional investors own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.